CRISPR Streamlines Goldenberry Growth to Enable Large-Scale Farming
Many people have never heard of the Goldenberry fruit (Physalis peruviana) before; it is a sweet tasting, minor crop that some consider to be a superfood because of its high…
Meet the Next Generation of Benchtop Sequencing Systems
View eBook With the MiSeq™ i100 Series, Illumina continues to set the highest standards. Advancements in system design, sequencing chemistry, and data analysis deliver the simplest, fastest benchtop sequencing and…
The Case for Endogenous Tagging
Sponsored content brought to you by Overcoming artifacts and capturing an accurate view of protein dynamics Understanding how proteins behave in living systems is central to biology. Yet, for decades,…
Cracking the Code of Francis Crick
In a special edition of GEN Live to wrap up 2025, we are thrilled to welcome special guest Matthew Cobb, PhD, author of a wonderful new biography of Francis Crick,…
Improving Astrocyte Function Shows Promise for Alzheimer’s
The link between Alzheimer’s disease and amyloid plaques is well documented, with innumerable studies exploring techniques and therapies to inhibit plaque formation, preventing development or progression of the disease. But…
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial
Credit: TopMicrobialStock / Adobe Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis…
Acyclovir-Activated Poison Exon Enables Reversible Gene Expression
Credit: Tanatpon Chaweewat / iStock / Getty Images Plus What if you could flip a genetic switch to silence a gene, then turn it back on with a simple drug?…
uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate
uniQure has acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130 may…
StockWatch: Intellia Shares Sink as Clinical Hold Follows Safety Setback
John Leonard, MD, Intellia Therapeutics president and CEO Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John Leonard, MD, announced that, given greater-than-expected patient enrollment in a…
Turbocharging Cas9’s Nuclear Entry
Christopher Doyle, PhDSenior Director, IBC ServicesWCG Clinical Advanced engineered cell therapies require gene editing tools that are both precise and efficient. In recent years, CRISPR-Cas9 has emerged as the gold…